Logo for MannKind Corporation

MannKind Investor Relations Material

Latest events

Logo for MannKind Corporation

Study Result

MannKind
Logo for MannKind

Study Result

16 Dec, 2024
Logo for MannKind

Q3 2024

7 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from MannKind Corporation

Access all reports
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.